Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Döhner

Showing results (11-20 of 490) with videos related to

Pageof 49
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2013
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemiaRichard F Schlenk, Hartmut Döhner
Blood|November 9, 2023
How I treat refractory and relapsed acute myeloid leukemiaFelicitas Thol, Hartmut Döhner, Arnold Ganser
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implicationsGuido Marcucci, Torsten Haferlach, Hartmut Döhner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2017
Genomics of Acute Myeloid Leukemia Diagnosis and PathwaysLars Bullinger, Konstanze Döhner, Hartmut Döhner
Haematologica|December 6, 2006
Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigensJochen Greiner, Hartmut Döhner, Michael Schmitt
Best Practice & Research. Clinical Haematology|August 21, 2007
Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemiaThorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer
The Lancet. Haematology|August 31, 2023
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' replyHartmut Döhner, Axel Benner, Arnold Ganser
Current Drug Targets|November 1, 2006
Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemiaDirk Winkler, Hartmut Döhner, Stephan Stilgenbauer
Seminars in Oncology|April 18, 2006
Risk stratification in chronic lymphocytic leukemiaTill Seiler, Hartmut Döhner, Stephan Stilgenbauer
Current Opinion in Hematology|January 27, 2007
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advancesKrzysztof Mrózek, Hartmut Döhner, Clara D Bloomfield
Pageof 49

Showing results (11-20 of 490) with videos related to

Sort By:
Pageof 49
Hematology. American Society of Hematology. Education Program|December 10, 2013
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemiaRichard F Schlenk, Hartmut Döhner
Blood|November 9, 2023
How I treat refractory and relapsed acute myeloid leukemiaFelicitas Thol, Hartmut Döhner, Arnold Ganser
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implicationsGuido Marcucci, Torsten Haferlach, Hartmut Döhner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2017
Genomics of Acute Myeloid Leukemia Diagnosis and PathwaysLars Bullinger, Konstanze Döhner, Hartmut Döhner
Haematologica|December 6, 2006
Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigensJochen Greiner, Hartmut Döhner, Michael Schmitt
Best Practice & Research. Clinical Haematology|August 21, 2007
Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemiaThorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer
The Lancet. Haematology|August 31, 2023
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' replyHartmut Döhner, Axel Benner, Arnold Ganser
Current Drug Targets|November 1, 2006
Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemiaDirk Winkler, Hartmut Döhner, Stephan Stilgenbauer
Seminars in Oncology|April 18, 2006
Risk stratification in chronic lymphocytic leukemiaTill Seiler, Hartmut Döhner, Stephan Stilgenbauer
Current Opinion in Hematology|January 27, 2007
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advancesKrzysztof Mrózek, Hartmut Döhner, Clara D Bloomfield
Pageof 49